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COVID-19, caused by infection with SARS-CoV-2, is a disease 
characterised by cough, fever and fatigue, which progresses to 
life-threatening lung injury in approximately 5% of patients. 
The SARS-CoV-2 virus enters the cell via ACE2. ACE2 is a 
component of the renin–angiotensin system (RAS) which has 
an important counterregulatory effect on the classical ACE-
dependent pathway. Several antihypertensives increase ACE2 
expression or activity, leading to concern that this may facilitate 
SARS-CoV-2 entry and worsen COVID-19 disease. However, 
ACE2 is protective against lung injury while ANG II (which is 
catabolised by ACE2) is associated with lung injury both in 
mice and humans. We propose that medications which inhibit 
the RAS ACE-dependent pathway may be beneficial in treating 
COVID-19 and should be explored in animal models and clinical 
trials. Here we give an overview of the RAS pathway with respect 
to COVID-19 and argue that strategies which manipulate this 
pathway might reduce the destructive lung manifestations of 
COVID-19 and improve patient outcomes.




SARS-CoV-2 is a novel coronavirus first identified at the end of 2019 
as a cluster of pneumonias associated with exposure to a seafood 
wholesale market in Wuhan, China,1 which has since spread around 
the world. The most common symptoms of the disease it causes, 
COVID-19, are fever, fatigue and a dry cough and it has a reported 
mortality rate of 4.3%.2 The current COVID-19 pandemic arguably 
represents the greatest disease threat to the human population in 
a century. Urgent clinical studies are required to identify effective 
therapeutic strategies.
COVID-19 disease predominantly affects individuals with 
comorbidities, including hypertension (31.2% of hospitalised 
patients), cardiovascular disease and diabetes.2 Patients with
Key points
 > The renin–angiotensin system (RAS) has two pathways, the 
ACE-mediated vasoconstrictive side and the ACE2-mediated 
vasodilative side. Commonly used antihypertensives target 
the ACE-mediated pathway and indirectly promote the 
ACE2-mediated pathway.
 > ACE2 is the viral entry receptor for SARS-CoV-2 and its 
expression may be affected by RAS-blocking drugs. However, 
there is currently no evidence that these drugs enhance viral 
entry into cells and hence patients are advised to continue 
their usual antihypertensive medications.
 > Once COVID-19 infection has taken place, virus binding is 
likely to prevent ACE2 mediating its usual pneumoprotective 
effects. Hence drugs targeting the opposing ACE 
pathway may represent a potential therapeutic strategy in 
infected patients at risk of lung injury.
hypertension are more likely to require intensive care unit (ITU) 
care (58.3% of those who were admitted to ITU had hypertension 
compared to 21.6% of those who were not).2 Because SARS-CoV-2 
enters cells via interaction between its surface spike glycoprotein  
and the cell surface angiotensin converting enzyme 2 (ACE2),3  
there is interest in the possibility of using medications which  
affect the renin–angiotensin system (RAS), of which ACE2 is a  
major component.
ACE2 and its role in COVID-19
The RAS is composed of two pathways. Both pathways begin with 
renin, which is produced by the kidney, converting angiotensinogen 
from the liver into angiotensin I (ANG I). In the first pathway, ANG 
I is converted to angiotensin II (ANG II) by angiotensin-converting 
enzyme (ACE). ANG II binds to its receptor, ANG II type 1 receptor 
(AT1R). This increases blood pressure by causing vasoconstriction 
and sodium retention. The second pathway is an ACE-independent 
pathway whereby a different enzyme, ACE2, converts ANG I to 
angiotensin-1-9 (ANG-1-9) and ANG II to ANG-1-7. ANG-1-7 
interacts with two different receptors, Mas and ANG II type 2 (AT2R) 
receptor. This pathway works to oppose the actions of the ACE- 
dependent pathway by causing vasodilation, hence lowering blood 
pressure as well as having other cardioprotective effects.4
ACE2 is a transmembrane protein with a carboxymonopeptidase 
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activity4 and is an integral component of the second, ACE-
independent, pathway. It is this protein which acts as the viral entry 
receptor for the recently identified SARS-CoV-2.3 ACE2 is localised 
to lung alveolar epithelial cells, small intestine enterocytes, venous 
and arterial endothelial cells and arterial smooth muscle. Therefore 
the lungs, and potentially also the small intestine, are the likely sites 
of SARS-CoV-2 viral entry into the body and the sites of maximal 
cell infection.5 This localisation of ACE2 has several implications for 
understanding the pathophysiology of the disease and could also 
be important for the development of certain treatments. Moreover, 
the expression of ACE2 in the lining of blood vessels is of note, 
as it could contribute to the risk of thrombotic events in patients 
with COVID-19, potentially via virion entry causing endothelial 
inflammation.6 In addition, the interaction between ACE2 and the 
coronavirus virion could act as a target for vaccines. For example, 
a recent study characterising the receptor-binding domain of the 
viral spike protein, which interacts with ACE2, suggested that this 
protein could be used as a vaccine target which would prevent 
COVID-19 infection.7 Interestingly, the ACE2 gene is carried on 
the X chromosome,8 which may possibly account for the apparent 
increased susceptibility of men to COVID-19, compared to 
women.2 This may be due to differential affinity of polymorphic 
variants of the ACE2 gene causing differential binding of SARS-
CoV-2 and, hence, relative protection in heterozygous women 
compared with hemizygous men or, alternatively, due to functional 
haploinsufficiency in men and reduced ACE2 gene dosage.
Antihypertensive drugs and COVID-19
As the RAS is integral to cardiac homeostasis and the control of 
blood pressure, drugs which interfere with the system are used as 
antihypertensives. Such medications include ACE inhibitors (ACEIs), 
such as lisinopril, and angiotensin II receptor blockers (ARBs), such 
as losartan. While investigating the effects of RAS blockade on ACE2, 
which is not sensitive to blockade by ACEIs, Ferrario et al found that 
lisinopril and losartan alone increased expression of cardiac ACE2 
mRNA in mice. Combined, these medications caused increased ACE2 
activity but did not increase ACE2 mRNA expression. In addition, 
the ACEI increased plasma ANG-1-7 1.8-fold and decreased plasma 
ANG II. The ARB resulted in increased plasma levels of both ANG II 
and ANG-1-7 and increased cardiac ACE2 activity. ACEIs and ARBs 
therefore likely do not only lower blood pressure by inhibiting the first 
(ACE-dependent) pathway of RAS, but also by stimulating the second 
ACE2-dependent pathway, which has negative regulatory effects on 
the first pathway.9
Because SARS-CoV-2 enters the cell via ACE2, there was concern 
about the possibility of RAS-inhibiting drugs exacerbating COVID-19 
infection by facilitating increased viral infection of cells, and this 
therefore raised the question of whether patients currently taking 
these drugs should stop or change them.10 This was especially relevant 
as patients with comorbidities including hypertension, cardiovascular 
disease and diabetes are at greater risk of COVID-19, and may develop 
a more severe infection, potentially necessitating ITU intervention, 
and are also more likely to be taking these medications.2 However, at 
present there is no evidence that the use of ACEIs or ARBs increases 
the risk of mortality in COVID-19 patients.11–13 Although it can be 
argued that there is a hypothetical risk of increasing the number of 
cells infected by the virus in patients who take these medications, 
there needs to be a critical assessment of the risks of stopping 
them, such as increased risk of morbidity or mortality due to heart 
failure, hypertensive complications and worsening of chronic kidney 
disease.14,15 On this basis, there is insufficient evidence to support 
abruptly stopping these medications in patients who take them in the 
community who are found to be positive for COVID-19. This conclusion 
is echoed by the European Society of Cardiology, who recommend 
that COVID-19 patients do not stop their ACEIs or ARBs.16
The renin–angiotensin system 
Fig 1. COVID-19 and the renin-angiotensin system. Diagram showing the dual ACE- and ACE2-dependent pathways and the potential for therapeutic inter-
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The role of RAS imbalance in lung injury:  
a therapeutic target?
Although RAS-inhibiting drugs merit caution given the above, there 
is also evidence to suggest that increased ACE2 expression may be 
beneficial in COVID-19 patients. SARS-CoV (a different coronavirus 
which caused the severe acute respiratory distress syndrome [SARS] 
outbreak in 2003) utilises the same receptor for viral entry and 
subsequently downregulates expression of ACE2 on the cell surface 
in vitro.17 In addition, injection of the SARS spike protein in wild-type 
mice resulted in reduced lung function, whereas this effect was 
mitigated in ACE2-knockout mice, suggesting that the lung injury 
caused by the spike protein is dependent on modulating ACE2.17 
When Imai et al compared the effect of acid aspiration and sepsis 
(frequent causes of acute respiratory distress syndrome) in wild-
type and ACE2 knockout mice, they found that the lung damage 
increased inflammation, bleeding and oedema to a greater extent 
in the knockout mice compared to wild type. Rescue experiments 
using injected recombinant human ACE2 protein decreased the 
severity of insult induced by lung injury. Similarly, they found that 
AT2R knockout mice had worsened insult-induced lung injury. This 
suggests that ACE2 and AT2R are pneumo-protective. Conversely, 
while they found that ACE, ANG II and AT1R promoted lung 
damage following a respiratory insult,18 ACE2 protects against lung 
injury, likely by converting ANG I to ANG-1-9 and ANG II to ANG-1-
7, leading to reduced levels of ANG II and reduced pneumo-damage 
mediated via AT1R binding.18
A recent study of 12 hospitalised COVID-19 patients compared 
their ANG II levels to healthy controls. They found that the ANG II 
levels in COVID-19 patients were significantly elevated compared to 
healthy controls. In addition, they found that the ANG II level was 
correlated with their viral load and lung injury.19 Thus, there appears 
to be evidence for an imbalance of the RAS in the lungs of patients 
with COVID-19 which could explain the pathogenesis of the disease. 
This may be one of the mechanisms by which COVID-19 results in 
severe lung injury, the most common complication of the disease, 
affecting 61% of hospitalised patients.2
Although the obvious choice for a treatment for COVID-19 may be 
a compound with antiviral properties, we believe that there is strong 
evidence to support investigating the use of RAS-inhibiting drugs 
alongside antiviral strategies. The rationale here is that RAS-blocking 
drugs, which increase the activity of ACE2,9 would reduce the levels 
of pneumo-damaging peptides, in particular ANG II. This should 
be explored urgently in animal models of the disease with a view 
to progressing to clinical trials in COVID-19 patients. Only then can 
we confirm the viability of this approach in reducing lung damage 
associated with SARS-CoV-2 infection. We suggest investigating the 
use of three different inhibitors of RAS.
We propose that direct inhibition of upstream renin with aliskiren 
might help to restore the angiotensin imbalance, triggered by SARS-
CoV-2 cell entry, by preventing conversion of angiotensinogen to 
angiotensin I. Aliskiren, the only renin inhibitor approved for clinical 
use, has not featured significantly in discussions of RAS inhibitors 
in COVID-19, which has largely focused on the more commonly 
utilised ACEIs and ARBs instead. However, targeted inhibition of 
the initiating step of the RAS pathway may prevent downstream 
consequences caused by COVID-19-mediated loss of ACE2. An 
alternative approach is to use ACEIs with the aim of reducing levels 
of ANG II, which are high in COVID-19 patients,19 and thereby 
increasing levels of ANG-1-9 and ANG-1-7.20 Finally, ARBs, which 
are selective for the pneumo-damaging AT1R and not the pneumo-
protective AT2R,20 might serve to help minimise downstream lung 
injury by blocking binding of ANG II to AT1R (Fig 1).
In support of this proposal, a recent observational study from 
China has shown that among hospitalised COVID-19 patients 
with hypertension, inpatient use of ACEIs/ARBs was associated 
with lower risk of all-cause mortality compared with ACEI/ARB 
non-users.13 There might also be theoretical therapeutic benefit 
from combining the three different RAS inhibitor drugs in order 
to generate stepwise blockade of the RAS pathway and restore 
some balance of ANG I/II and ANG-1-7/-1-9. However, clinical 
trials of combination therapy in hypertension treatment, such as 
the ALTITUDE study, have resulted in excess adverse events21 and 
therefore extreme caution would have to be applied.
Conclusion
ACE2 is essential for the pathogenesis of SARS-CoV-2 by mediating 
viral entry. COVID-19 infection leads to ACE2 depletion, triggering 
an imbalance in RAS peptides, notably accumulation of ANG II 
and likely reduction of ANG-1-9 and ANG-1-7. RAS inhibitor drugs 
targeting the ACE side of the system, and hence increasing activity 
of the ACE2 pathway, have the potential to reduce COVID-19 
associated lung damage and, if found to be safe and effective 
in animal studies, should be studied urgently in clinical trials of 
COVID-19 patients. These drugs are all immediately available 
and could potentially have a beneficial impact on mortality levels 
currently experienced in the COVID-19 pandemic.  
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